After the monoclonal antibody nirsevimab (Beyfortus) became available to prevent respiratory syncytial virus (RSV) in infants ...

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized ...

RSV infects the lungs, causing pneumonia or bronchiolitis. While most children recover from RSV, it can be fatal, especially ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in ...

New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to hospital each year.

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

“Initial conversations were often about imagining what does 28 years later mean? If the infection is still in Britain, what does the infection look like?,” said Garland. “How does the rest ...